Cibc World Market Inc. Buys 2,574 Shares of Waters Corporation $WAT

Cibc World Market Inc. grew its position in Waters Corporation (NYSE:WAT) by 73.3% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 6,085 shares of the medical instruments supplier’s stock after purchasing an additional 2,574 shares during the period. Cibc World Market Inc.’s holdings in Waters were worth $2,282,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in the company. Castlefield Investment Partners LLP increased its position in shares of Waters by 107.6% during the 2nd quarter. Castlefield Investment Partners LLP now owns 1,553 shares of the medical instruments supplier’s stock worth $582,000 after purchasing an additional 805 shares in the last quarter. Sanctuary Advisors LLC boosted its position in Waters by 2.6% in the second quarter. Sanctuary Advisors LLC now owns 4,462 shares of the medical instruments supplier’s stock valued at $1,673,000 after buying an additional 115 shares in the last quarter. Meiji Yasuda Asset Management Co Ltd. grew its stake in Waters by 1,223.4% during the second quarter. Meiji Yasuda Asset Management Co Ltd. now owns 11,593 shares of the medical instruments supplier’s stock worth $4,348,000 after buying an additional 10,717 shares during the last quarter. Daiichi Life Insurance Co. Ltd. grew its stake in Waters by 3.7% during the second quarter. Daiichi Life Insurance Co. Ltd. now owns 2,693 shares of the medical instruments supplier’s stock worth $1,010,000 after buying an additional 97 shares during the last quarter. Finally, Foyston Gordon & Payne Inc increased its holdings in shares of Waters by 2.1% during the second quarter. Foyston Gordon & Payne Inc now owns 5,738 shares of the medical instruments supplier’s stock worth $2,152,000 after buying an additional 117 shares in the last quarter. Institutional investors own 94.01% of the company’s stock.

Waters Price Performance

Shares of WAT stock opened at $415.07 on Thursday. Waters Corporation has a 1 year low of $282.77 and a 1 year high of $421.74. The firm’s 50 day moving average is $385.08 and its 200-day moving average is $347.72. The firm has a market capitalization of $40.78 billion, a price-to-earnings ratio of 103.51, a PEG ratio of 2.41 and a beta of 1.19. The company has a current ratio of 1.86, a quick ratio of 1.29 and a debt-to-equity ratio of 0.32.

Waters (NYSE:WAT) last issued its quarterly earnings results on Tuesday, August 4th. The medical instruments supplier reported $3.05 earnings per share for the quarter, beating analysts’ consensus estimates of $3.01 by $0.04. The business had revenue of $1.65 billion during the quarter, compared to analyst estimates of $1.62 billion. Waters had a net margin of 3.58% and a return on equity of 11.27%. Waters’s revenue for the quarter was up 113.3% compared to the same quarter last year. During the same quarter last year, the business posted $2.95 earnings per share. Waters has set its Q3 2026 guidance at 3.950-4.050 EPS and its FY 2026 guidance at 14.450-14.650 EPS. Sell-side analysts forecast that Waters Corporation will post 14.56 EPS for the current fiscal year.

Insider Buying and Selling

In other Waters news, Director Christopher A. Kuebler sold 3,626 shares of the stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $397.94, for a total value of $1,442,930.44. Following the transaction, the director directly owned 17,808 shares in the company, valued at approximately $7,086,515.52. This trade represents a 16.92% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.31% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. Robert W. Baird set a $387.00 target price on shares of Waters in a research note on Wednesday, May 6th. Wolfe Research initiated coverage on Waters in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $425.00 price target on the stock. Royal Bank Of Canada raised their price target on Waters from $435.00 to $475.00 and gave the company an “outperform” rating in a report on Wednesday, August 5th. Wells Fargo & Company lifted their price objective on Waters from $370.00 to $400.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 5th. Finally, UBS Group boosted their price objective on Waters from $330.00 to $375.00 and gave the stock a “neutral” rating in a research note on Wednesday, May 6th. Three equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $420.35.

Waters Company Profile

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.